Inhibikase Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2026, the registrant had 132,032,636 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March31, 2026 and 2025 (Unaudited)2Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and2025 (Unaudited)3Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(Unaudited)5Notes to Unaudited Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28PART II.OTHER INFORMATIONItem 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds29Item 3.Defaults Upon Senior Securities29Item 4.Mine Safety Disclosures29Item 5.Other Information29Item 6.Exhibits30Signatures31 We own various United States (“U.S.”) federal trademark applications and unregistered trademarks, including our company nameand logo, that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q (this “QuarterlyReport”) includes our trademarks and trade names which are protected under applicable intellectual property laws and are ourproperty. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are theproperty of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this QuarterlyReport may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will notassert, to the fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks,trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks toimply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by theseother parties. From time to time, we may use our website and our LinkedIn account at https://www.linkedin.com/company/inhibikase-therapeutics/ to distribute material information about us and for complying with our disclosure obligations under Regulation FD.Our financial and other material information is routinely posted to and accessible on the Investors section of our website, availableathttps://www.inhibikase.com/. Investors are encouraged to review the Investors section of our website because we may postmaterial information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessedthrough our website or our social media is not incorp